Phase I Trial of 17-Dimethylaminoethylamino-17-Demethoxygeldanamycin (17-DMAG), a Heat Shock Protein Inhibitor, Administered Twice Weekly in Patients with Advanced Malignancies

PURPOSE: Phase I dose-escalation study to determine the toxicity and maximum tolerated dose (MTD) of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), a heat shock protein 90 (Hsp90) inhibitor, administered on a twice weekly schedule in patients with advanced cancer. EXPERIMENTAL DESIGN...

詳細記述

保存先:
書誌詳細
主要な著者: Kummar, Shivaani, Gutierrez, Martin E., Gardner, Erin R., Chen, Xiaohong, Figg, William D., Zajac-Kaye, Maria, Chen, Min, Steinberg, Seth M., Muir, Christine A., Yancey, Mary Ann, Horneffer, Yvonne R., Juwara, Lamin, Melillo, Giovanni, Ivy, S. Percy, Merino, Maria, Neckers, Len, Steeg, Patricia S., Conley, Barbara A., Giaccone, Giuseppe, Doroshow, James H., Murgo, Anthony J.
フォーマット: Artigo
言語:Inglês
出版事項: 2009
主題:
Article
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC2818572/
https://ncbi.nlm.nih.gov/pubmed/19945858
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ejca.2009.10.026
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料